# SERB Pharmaceuticals

Source: https://onco.cc/companies/serb-pharmaceuticals/  
OnCo record `serb-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SERB is a European specialty company focused on emergency and rescue medicines; in oncology it markets glucarpidase (Voraxaze) for toxic methotrexate levels and uridine triacetate (Vistogard) for fluorouracil overdose in Europe.

## Summary

SERB Pharmaceuticals, based in Paris, is a European specialty company focused on emergency and rescue medicines; in oncology it markets glucarpidase, sold as Voraxaze, for toxic methotrexate levels and uridine triacetate, sold as Vistogard, for fluorouracil overdose in Europe. It acquired BTG's specialty pharmaceuticals business in 2021, adding Voraxaze, CroFab and DigiFab, and distributes antidotes and rescue therapies used in oncology supportive care. OnCo links it to glucarpidase, uridine triacetate and telotristat ethyl. Whether rarely used antidotes remain stocked and affordable when a single company holds them is the question that matters for the patients who suddenly need them. Glucarpidase has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Paris
- Type: pharma
- Website: https://www.serb.eu

## Sources

- Official website: https://www.serb.eu

## Connected records

- key papers: [Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity](https://onco.cc/key-papers/paper-vistogard-cancer-2017/)
- drugs: [Glucarpidase](https://onco.cc/drugs/glucarpidase/), [Telotristat ethyl](https://onco.cc/drugs/telotristat-ethyl/), [Uridine triacetate](https://onco.cc/drugs/uridine-triacetate/)

---
JSON: https://onco.cc/api/v1/entities/serb-pharmaceuticals.json